Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).

Autor:	Vermehren J; Gastro-Praxis Wiesbaden, Wiesbaden, Germany.; University Hospital Frankfurt, Frankfurt am Main, Germany., Serfert Y; Leberstiftungs-GmbH Deutschland, Hannover, Germany., Cornberg M; Hannover Medical School, Hannover, Germany., Stoehr A; ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany., Klinker H; University Hospital Würzburg, Würzburg, Germany., Simon KG; MVZ Dres. Eisenbach, Simon, Schwarz GbR, Leverkusen, Germany., Teuber G; Hepatologische Schwerpunktpraxis, Frankfurt am Main, Germany., Deterding K; Hannover Medical School, Hannover, Germany.; Essen University Hospital, University of Duisburg-Essen, Essen, Germany., Schulze Zur Wiesch J; University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany., Jung MC; Leberzentrum München, München, Germany., Manns MP; Hannover Medical School, Hannover, Germany., Zeuzem S; University Hospital Frankfurt, Frankfurt am Main, Germany., Wedemeyer H; Leberstiftungs-GmbH Deutschland, Hannover, Germany.; Hannover Medical School, Hannover, Germany.; Essen University Hospital, University of Duisburg-Essen, Essen, Germany., Sarrazin C; University Hospital Frankfurt, Frankfurt am Main, Germany.; St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany.
Jazyk:	angličtina
Zdroj:	Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2020 Sep; Vol. 58 (9), pp. 841-846. Date of Electronic Publication: 2020 Sep 18.
DOI:	10.1055/a-1217-7669
Abstrakt:	Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies. Competing Interests: Johannes Vermehren: sponsored lectures (national oriInternational): AbbVie, Gilead, Intercept, Merck. Markus Cornberg: sponsored lectures (national or international): AbbVie, Gilead, Merck/MSD, Siemens Healthcare, Falk Foundation e. V.; other: advisory committee or review panel: Merck/MSD, AbbVie, Spring. Albrecht Stoehr: grants: Abbvie, Bristol-Myers-Squibb, Gilead, Janssen, MSD, ViiV; sponsored lectures (national or international): AbbVie, Bristol-Myers-Squibb, Gilead, Janssen, MSD, ViiV; other: advisory boards: AbbVie, Bristol-Myers-Squibb, Gilead, Janssen, MSD, ViiV. Hartwig Klinker: grants: Abbvie, BMS, Gilead, Janssen, MSD; sponsored lectures (national or international): AbbVie, BMS, Gilead, Janssen, MSD; other: advisory boards: AbbVie, BMS, Gilead, Hexal, Janssen, MSD. Karl-Georg Simon: sponsored lectures (national or international): AbbVie, FALK, Gilead, MSD; other: advisory committee or review panel: AbbVie, MSD. Gerlinde Teuber: sponsored lectures (national or international): AbbVie, Gilead Sciences, Intercept, MSD; other: advisory committee or review panel: AbbVie, Gilead. Katja Deterding: sponsored lectures (national or international): AbbVie, Gilead, Merck/MSD; other: advisory committee: Gilead, AbbVie. Julian Schulze zur Wiesch: sponsored lectures: Gilead, MSD, AbbVie. Maria-Christina Jung: nothing to disclose. Yvonne Serfert: nothing to disclose. Michael P. Manns: grants: AbbVie, BMS, Janssen, Gilead, Merck (MSD); sponsored lectures (national or international): AbbVie, BMS, Janssen, Gilead, Merck (MSD); consultant: AbbVie, BMS, Janssen, Gilead, Merck (MSD). Stefan Zeuzem: consultancies and lecture honoria: AbbVie, Gilead, Intercept, Janssen, Merck/MSD. Heiner Wedemeyer: reports personal fees from Transgene, MSD, Roche, Gilead, Abbott, BMS, Falk, AbbVie, Novartis, GSK, Roche Diagnostics, Eiger, ITF, and MyrGmbH; grants/research support from MSD, Novartis, Gilead, Roche, Abbott, and Roche Diagnostics. Christoph Sarrazin: grants: Abbott, Gilead, Janssen, Qiagen, Roche, Siemens; sponsored lectures (national or international): Abbott, AbbVie, Achillion, BMS, Gilead, Janssen, Merck/MSD, Qiagen, Roche, Siemens; other: advisory boards: Abbott, AbbVie, BMS, Gilead, Janssen, Merck/MSD, Roche. (© Georg Thieme Verlag KG Stuttgart · New York.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu